Examination of the relationship between serum zinc levels and peripheral neuropathy induced by paclitaxel/carboplatin combination therapy in gynecological cancer patients
Objectives: Chemotherapy-induced peripheral neuropathy (CIPN), a frequently occurring adverse event associated with paclitaxel/carboplatin (TC) combination therapy, causes limb pain and markedly reduces the patient’s quality of life. Since zinc has been reported to be associated with neuropathic p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Fujita Medical Society
2025-02-01
|
| Series: | Fujita Medical Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/fmj/11/1/11_2024-013/_pdf/-char/ja |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objectives: Chemotherapy-induced peripheral neuropathy (CIPN), a frequently occurring adverse event associated
with paclitaxel/carboplatin (TC) combination therapy, causes limb pain and markedly reduces the patient’s quality of
life. Since zinc has been reported to be associated with neuropathic pain, we investigated the relationship between
CIPN due to TC therapy and serum zinc levels.
Methods: The study included 13 patients with gynecological cancer whose serum zinc levels were measured before
and during TC therapy. CIPN was classified into severity grades based on the Common Terminology Criteria for
Adverse Events v5.0. A retrospective analysis was conducted on the relationship between the serum zinc level
before TC therapy (PreZn), the minimum serum zinc level measured during TC therapy (MinZn), the MinZn/PreZn
ratio, the number of TC treatment cycles, and the maximum grade of CIPN (MaxG) using Pearson’s correlation
coefficient. Moreover, an analysis was also conducted on clinical factors influencing MaxG, as well as fluctuations in
serum zinc levels and CIPN grades for each cycle of TC therapy.
Results: A negative correlation was observed between the MinZn/PreZn ratio and MaxG (r=–0.557, p=0.048). The
clinical factors influencing CIPN remained unclear, and the decrease in serum zinc levels and the aggravation of
CIPN plateaued after the third cycle.
Conclusions: If a decrease in serum zinc levels during TC therapy is smaller than before therapy, it may imply the
existence of a causal relationship that suppresses the aggravation of CIPN. |
|---|---|
| ISSN: | 2189-7247 2189-7255 |